CClinicalTrials.gg
CompletedNCT06450795Updated Sep 22, 2026

Effectiveness of High Intensity Electromagnetic Therapy and Pelvic Floor Exercises in Women With Urinary Incontinence

An interventional study of Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists. in Urinary Incontinence, sponsored by Istanbul Medipol University Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Istanbul Medipol University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
Female
01

Study summary

The aim of this study is to evaluate the effect of pelvic floor exercises and high intensity electromagnetic therapy on pelvic floor muscle function, quality of life and urinary parameters in women with stress urinary incontinence. The individuals to be included in the study will be selected from women with stress urinary incontinence who receive follow-up from Medipol Acıbadem Hospital. Women who meet the inclusion criteria will be explained the details of the study by the responsible researcher and an informed consent form will be presented. The study is planned as two groups:

Group 1: Pelvic floor muscle training (PBST) group. Group 2: Pelvic floor muscle training and high intensity functional electromagnetic stimulation (HIFEM) treatment group.

Envelope opening method will be used for randomisation of the participants into two groups. They will be included in the first or second group according to the number in the envelope they choose.

Each participant will be given a baseline assessment. Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists. Participants in 2 groups will also receive HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.

Research Outcome Measures:

Demographic and Clinical Characteristics International Incontinence Consultation Questionnaire-Short Form Urogenital Distress Inventory (UDI-6) Quality of Life King Health Survey Muscle function Emg-Biofeedback

02

Conditions studied

  • Urinary Incontinence

Keywords

  • electromagnetic stimulation
  • urinary incontinence
  • pelvic floor muscle training
03

In context

Urinary Incontinence

1,363 studies on the registry are indexed under Urinary Incontinence; 228 are open to participants now.

This study's enrollment of 44 is below the median of 66 across 1,011 interventional studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

Istanbul Medipol University Hospital is the lead sponsor of 350 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed as stress urinary incontinence by a physician,
  • Between the ages of 20-65,
  • Has not had recurrent vaginitis infection,
  • Women with no active urinary tract infection or more than 3 urinary tract infections in the last 1 year will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • History of cardiac implant or untreated cardiac arrhythmia,
  • The presence of a metal implant,
  • Vaginal and pelvic surgery within the last 6 months,
  • Gave birth within the last 12 weeks and had a history of miscarriage within 6 weeks,
  • A recent surgical procedure,
  • Any concurrent UI treatment,
  • With renal and hepatic insufficiency,
  • Neurological or neuromuscular disease
  • It will be excluded in case of any contraindication listed in the investigational device manual.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    High intensity functional electromagnetic stimulation (HIFEM) treatment group

    Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists. Additionally, Participants will also receive HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.

    Behavioral: Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.

  • Experimental
    Pelvic floor muscle training group

    Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.

    Behavioral: Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.

Interventions

  • BehavioralParticipants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.

    HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.

    Also known as: high intensity functional electromagnetic stimulation

06

What researchers measure

Primary outcomes

  1. International Incontinence Consultation Questionnaire-Short Form

    Urinary incontinence symptom severity and its effect on quality of life will be evaluated with the ICIQ-SF, the reliability and validity of the Turkish version of which was performed by Çetinel et al. The scale consists of a total of 6 items questioning the type, frequency and amount of urinary incontinence and the effects of incontinence on the individual's life. The scores that can be obtained from the scale vary between 0-21 and a higher score indicates an increase in the severity of incontinence.

    Time frame: 5 minute

  2. Urogenital Distress Inventory (UDE-6)

    The UDI-6 consists of 6 questions and is graded with a 4-point Likert-type score. A minimum score of 0 is obtained from the UDE-6 and this means that 'the patient is not disturbed at all', while the maximum score of 18 means that 'the patient is extremely disturbed by the symptoms'. The scores are converted to a percentage and the score is determined. The higher the score, the greater the severity of the symptoms.

    Time frame: 5 minute

  3. King's Health Questionnaire

    The reliability and validity of the Turkish version of the quality of life related to urinary symptoms will be evaluated with the KSA, which was studied by Kaya et al. The KSA consists of two parts and includes 32 items. The best score that can be obtained from the complaint severity scale is '0' and the worst score is '30', while the best score that can be obtained from the answers given to all KSA sub-section problems is '0' and the worst score is '100'.

    Time frame: 5 minute

  4. EMG-Biofeedback

    Used to evaluate pelvic floor muscle activation

    Time frame: 5 minute

07

Study locations

1 site
  • Istanbul Medipol University
    Istanbul, Turkey (Türkiye)
08

References and documents

Publications

  • Kilicoz Bakar M, Ozkocak G, Algun ZC. Comparison of High-Intensity Electromagnetic Therapy and Pelvic Floor Muscle Exercises in Women with Urinary Incontinence: A Randomized Controlled Trial. Int J Womens Health. 2026 Jul 8;18:612726. doi: 10.2147/IJWH.S612726. eCollection 2026. PubMed 42438479 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06450795
Lead sponsor
Istanbul Medipol University Hospital
Responsible party
mehtap kilicoz (PhD student, Medipol University) — Principal investigator
First posted
Jun 10, 2024
Start date
Jun 1, 2024
Primary completion
May 12, 2025
Completion
Aug 17, 2025
Last update
Sep 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion